Comparison of OptiNose (NASDAQ:OPTN) and Evelo Biosciences (NASDAQ:EVLO)


OptiNose (NASDAQ:OPTN – Get Rating) and Evelo Biosciences (NASDAQ:EVLO – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on institutional ownership strength, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Valuation and benefits

This table compares the revenue, earnings per share (EPS) and valuation of OptiNose and Evelo Biosciences.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
OptiNose $74.65 million 2.68 -$82.30 million ($1.48) -1.64
Evelo Biosciences N / A N / A -$122.18 million ($2.31) -1.07

OptiNose has higher revenues and profits than Evelo Biosciences. OptiNose trades at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

OptiNose has a beta of 0.51, which means its stock price is 49% less volatile than the S&P 500. In comparison, Evelo Biosciences has a beta of 1.67, which means its stock price is 67 % more volatile than the S&P 500.

Analyst Notes

This is a breakdown of the current ratings and recommendations for OptiNose and Evelo Biosciences, as reported by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
OptiNose 0 0 2 0 3.00
Evelo Biosciences 0 1 5 0 2.83

OptiNose currently has a consensus target price of $10.33, indicating a potential upside of 327.00%. Evelo Biosciences has a consensus target price of $21.92, indicating an upside potential of 787.31%. Given the likely higher upside of Evelo Biosciences, analysts clearly believe that Evelo Biosciences is more favorable than OptiNose.

Profitability

This table compares the net margins, return on equity and return on assets of OptiNose and Evelo Biosciences.

Net margins Return on equity return on assets
OptiNose -110.24% N / A -55.28%
Evelo Biosciences N / A -254.96% -97.27%

Insider and Institutional Ownership

62.3% of OptiNose shares are held by institutional investors. Comparatively, 90.8% of Evelo Biosciences shares are held by institutional investors. 6.0% of OptiNose shares are held by insiders. Comparatively, 6.1% of Evelo Biosciences shares are held by insiders. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock is poised for long-term growth.

OptiNose Company Profile (Get an assessment)

OptiNose, Inc., a specialty pharmaceutical company, is focused on developing and commercializing products for patients treated by ear, nose, throat and allergy specialists in the United States. Company offers XHANCE, a therapeutic product using its proprietary exhalation delivery system (EDS) that delivers a topical corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, and a Phase IIIb clinical trial for the treatment chronic sinusitis; and Onzetra Xsail, a powder EDS device. He is also developing OPN-019 which combines a liquid EDS device with an antiseptic. The company has a licensing agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import and sell products containing orexin receptor agonist molecules and/or orexin receptor positive modulator molecules for the treatment, diagnosis or prevention of disease or human conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Evelo Biosciences company profile (Get an assessment)

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in a Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as the hyperinflammatory response associated with COVID-19. The Company is also developing EDP1867, an investigational oral inactivated biologic drug, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an experimental oral biological extracellular vesicle for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.



Get news and reviews for OptiNose Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for OptiNose and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.